3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego, Marco Colleoni, Agostina Stradella, Begoña Bermejo, Florence Dalenc, Santiago Escrivá-de-Romaní, Lourdes Calvo Martínez, Nuria Ribelles, Frederik Marmé, Alfonso Cortés, Cinta Albacar, Géraldine Gebhart, Aleix Prat, Khaldoun Kerrou, Peter Schmid, Sofía Braga, Serena Di Cosimo, María Gión, Gabriele Antonarelli, Crina Popa, Emilia Szóstak, Daniel Alcalá-López, Petra Gener, José Rodríguez-Morató, Leonardo Mina, Miguel Sampayo-Cordero, Antonio Llombart‐Cussac